An Internist’s Perspective: Understanding Obesity and its Management
Judy Shiau, MD, Dipl.of ABOM – Associate Professor, Division of Endocrinology and Metabolism and Program Director for the Bariatric Medicine Fellowship at the University of Ottawa; General Internist and Medical Director of LEAF Weight Management Clinic

A Cardiologist’s Perspective: How I Treat my Patients with Obesity and CVD
(including AFib)
Aaron Aday, MD, MSc – Investigator, Vanderbilt Translational and Clinical Cardiovascular Research Center at Vanderbilt University Medical Center

A Hematologist’s Perspective: How I Treat my Patients with Obesity and VTE
Tzu-Fei Wang, MD, MPH – Associate Professor of Medicine at The University of Ottawa in the Division of Hematology

A Bariatric Surgeon’s Perspective: How I Treat my Anticoagulated Patients
Undergoing Bariatric Surgery
Malcolm K. Robinson, MD – Associate Professor at Harvard Medical School; Vice Chairman of the Department of Surgery for Clinical Operations, Surgical Director of Perioperative Services, and Director of the Nutrition Support Service at Brigham and Women’s Hospital

Case-Based Debates and Q&A:
Moderated by Dr. Allen Taylor, MD – Chairman of Cardiology at MedStar Heart and Vascular Institute

Case 1: DOAC Use in a Patient with Obesity and AFib
Aaron Aday, MD, MSc – Investigator, Vanderbilt Translational and Clinical Cardiovascular Research Center at Vanderbilt University Medical Center

Case 2: DOAC Use in a Patient with Obesity and VTE
Tzu-Fei Wang, MD, MPH – Associate Professor of Medicine at The University of Ottawa in the Division of Hematology

Case 3: DOAC Use in a Patient Who Has Undergone Bariatric Surgery
Malcolm K. Robinson, MD – Associate Professor at Harvard Medical School; Vice Chairman of the Department of Surgery for Clinical Operations, Surgical Director of Perioperative Services, and Director of the Nutrition Support Service at Brigham and Women’s Hospital

Panel Discussion

By the end of the session the participant will be able to:

• Describe best practices for defining and measuring obesity, and the complexity revolving around the management of obesity
• Recognize the unique clinical challenges that may impact DOAC use in patients with obesity
• Discuss the latest data on indications for DOAC use in patients with obesity, including atrial fibrillation, VTE, and in the setting of bariatric surgery
• Identify limitations of various guideline recommendations pertaining to DOAC use in patients with obesity
• Assess optimal prophylactic and therapeutic anticoagulation strategies in patients with obesity

ACCME Activity #202289556

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

• Aaron Aday, MD, MSc: Paid Consultant – OptumCare
• Allen Taylor, MD: Speaker – Amgen, Espirion
• Judy Shiau, MD, Dipl.of ABOM: Speaker – Bausch Health, Novonordisk, Abbvie; Advisor – Bausch Health, Novonordisk; Research Grant – Bausch Health, Nestle Health Science
• Tzu-Fei Wang, MD, MPH: Research Grant – Leo Pharma; Advisory Board – Servier

Individuals with no conflicts of interest to disclose: 

• Content reviewer: Charles J Turck, PharmD, BCPS, BCCCP, President, ScientiaCME
• Malcolm K. Robinson, MD

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

*Required to view Printable PDF Version